Pathologic staging of prostate carcinoma: What are the issues?

✍ Scribed by David J. Grignon; Wael A. Sakr

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 388 KB
• Volume: 78
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19960715)78:2<337::aid-cncr23>3.0.co;2-w

✦ Synopsis

BACKGROUND.

Stage is a significant predictor of outcome for patients with carcinoma of the prostate. The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) TNM staging system has gained general favor as the clinical staging system of choice for prostate carcinoma. With an increasing number of publications assessing prognostic markers for patients with carcinoma of the prostate, there is a need for the development of a uniform system of pathologic staging to support the clinical stage.

METHODS.

The literature related to pathologic prognostic markers for patients with carcinoma of the prostate, particularly with regard to staging, was reviewed. From this, issues important to the development of a pathologic correlate to the AJCCI UICC TNM system were identified.